Somerset Therapeutics, LLC received FDA approval for its intravenous Verapamil Hydrochloride ANDA, introducing another generic alternative to the widely used antihypertensive and antiarrhythmic drug. This launch is expected to intensify market competition against market leaders, potentially driving down pricing and increasing availability in the IV segment.